この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2026/7/231 分で読めます
Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS
ローカル自動翻訳 · 情報源の原言語
概要
The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this Notice to Modala Bio, Inc. (Modala), headquartered in Delaware.
情報源の原言語: Federal Register — Health and Human Services原文の発表を開く →